Trial · NCT04145349
Adverse events302
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 302
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 8 | 20 | 13 |
| other | Anaemia | Blood and lymphatic system disorders | Cyclophosphamide + Vinorelbine | 2 | 10 | 13 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 1 | 20 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Cyclophosphamide + Vinorelbine | 0 | 10 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 2 | 20 | 3 |
| other | Leukopenia | Blood and lymphatic system disorders | Cyclophosphamide + Vinorelbine | 0 | 10 | 0 |
| other | Lymphopenia | Blood and lymphatic system disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 1 | 20 | 1 |
| other | Lymphopenia | Blood and lymphatic system disorders | Cyclophosphamide + Vinorelbine | 0 | 10 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 11 | 20 | 28 |
| other | Neutropenia | Blood and lymphatic system disorders | Cyclophosphamide + Vinorelbine | 1 | 10 | 3 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 3 | 20 | 3 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cyclophosphamide + Vinorelbine | 0 | 10 | 0 |
| other | Angina pectoris | Cardiac disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 1 | 20 | 1 |
| other | Angina pectoris | Cardiac disorders | Cyclophosphamide + Vinorelbine | 0 | 10 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 2 | 20 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Cyclophosphamide + Vinorelbine | 0 | 10 | 0 |
| other | Tachycardia | Cardiac disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 1 | 20 | 1 |
| other | Tachycardia | Cardiac disorders | Cyclophosphamide + Vinorelbine | 1 | 10 | 1 |
| other | Hypothyroidism | Endocrine disorders | Ramucirumab + Cyclophosphamide + Vinorelbine | 2 | 20 | 2 |
| other | Hypothyroidism | Endocrine disorders | Cyclophosphamide + Vinorelbine | 0 | 10 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04145349/events